Previous 10 | Next 10 |
HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced the publication of a peer-reviewed article in the European Journal of Vasc...
HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional patent application titled “...
Krystal Biotech (KRYS) - The company announced presentations of clinical data for KB103 to treat DEB (dystrophic epidermolysis bullosa) and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome at t...
Pluristem Therapeutics (NASDAQ: PSTI ) has met its enrollment timelines sooner than expected relating to its Phase III study in critical limb ischemia (CLI). More news on: Pluristem Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
HAIFA, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant milestone in its ongoing dev...
Recent financing provides funding through multiple potentially value-creating milestones Providing short and mid-term milestones, targeting marketing and significant contracts HAIFA, Israel, April 23, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:P...
HAIFA, Isreal, April 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today t...
Pluristem Therapeutics (NASDAQ: PSTI ) is 12.9% lower after hours following a proposal to offer shares and warrants in a public offering, along with a concurrent registered direct offering. More news on: Pluristem Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read ...
HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today that it...
HAIFA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled the second cohort of six patients...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...